Back

EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency

European Heart Journal

2 April 2025
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY
You may be interested in
thumbnail
Congress Presentation
Glycoprotein VI inhibition
30 August 2024
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025
thumbnail
Congress Presentation
Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study
1 September 2019
thumbnail
Congress Presentation
Major bleeding in patients with acute pulmonary embolism: results from the COPE study
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources